High affinity cAMP-specific 3',5'-cyclic phosphodiesterase 7A (PDE7A1) (PDE7A1)

High affinity cAMP-specific 3',5'-cyclic phosphodiesterase 7A (PDE7A1) is an enzyme that specifically hydrolyzes the second messenger cyclic adenosine monophosphate (cAMP), thereby regulating its intracellular concentrations and downstream signaling pathways [2, 4, 10]. It is a splice variant of the PDE7A gene and is the predominant isoform found in T lymphocytes, where it plays a significant role in T-cell activation and immune responses [3, 6, 9]. PDE7A1 is also highly expressed in skeletal muscle and found at lower levels in the brain, heart, and other tissues [2, 9]. Due to its role in modulating cAMP-mediated inflammation and neuroprotection, PDE7A1 is considered a promising therapeutic target for a variety of conditions, including autoimmune diseases, respiratory disorders like asthma and COPD, and neurodegenerative diseases such as Parkinson's and Alzheimer's [5, 10, 12]. Research into PDE7A1 inhibitors aims to provide anti-inflammatory and neuroprotective effects with a potentially better safety profile than traditional PDE4 inhibitors, which are often limited by gastrointestinal side effects [3, 5]. While several selective and dual PDE4/7 inhibitors have been developed for research purposes, no PDE7A-specific drugs have yet reached clinical approval [10].

Other names

Phosphodiesterase 7AHCP1TM22cAMP-specific phosphodiesterase 7AHigh affinity cAMP-specific PDE 1

Selective inhibition of the PDE7A enzyme, preventing the hydrolysis of cAMP to 5'-AMP, which leads to an accumulation of intracellular cAMP and subsequent activation of protein kinase A (PKA) signaling pathways [5, 10]. Additionally, PDE7A1 has been shown to directly inhibit the catalytic subunit of PKA through a non-catalytic interaction [7].